

# SUPPLEMENTARY INFORMATION

## 其他資料

### Corporate Governance

Throughout the six months ended 30 September 2025 and up to the date of this interim report, we have complied with all but one of the code provisions under the Corporate Governance Code, Appendix C1 of the Listing Rules.

#### Code Provision C.2.1

Under code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. We have deviated from the code in that Dr KWOK Siu Ming Simon is both the chairman and CEO of the Company. The division of responsibilities between the two roles are, however, clearly established and set out in writing in the respective terms of reference for the chairman and the chief executive officer. Dr Kwok, being one of the founders of the Group, has superior knowledge of our business and is a veteran of the retail industry. The Board is therefore of the view that vesting the roles of chairman and chief executive officer in the same person facilitates the execution of the Group's business strategies and maximises the effectiveness of our operations. We will, nevertheless, periodically review the Board's structure going forward in light of the evolving needs of the Group and consider segregation of the two roles if and when appropriate.

#### Model Code

We have adopted our own model codes regarding securities transactions by directors and relevant employees on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules. Our model codes are extended to certain "relevant employees" who, because of their office or employment, are likely to possess inside information in relation to the Company or its securities. We have received confirmation from all Directors and relevant employees that they have complied with the Company's model codes throughout the period under review.

### Audit Committee

The unaudited interim results of the Group for the six months ended 30 September 2025 have not been reviewed by the independent auditor, but have been reviewed by the Audit Committee of the Company.

### Interim Dividend

The Board declared an interim dividend of 1.15 HK cents (2024: 0.75 HK cents) per share for the six months ended 30 September 2025, payable to Shareholders whose names appear on the register of members of the Company on Monday, 8 December 2025. The interim dividend is expected to be paid on or around Friday, 19 December 2025.

### 企業管治

截至2025年9月30日止六個月及直至本中期報告日期，除未能遵守其中一項守則條文，我們已遵守上市規則附錄C1之《企業管治守則》的所有守則條文。

#### 守則條文第C.2.1條

就《企業管治守則》的守則條文第C.2.1條，主席與行政總裁的角色應有區分，並不應由一人同時兼任。由於郭少明博士現身兼本公司主席及行政總裁兩職，我們偏離了守則條文。但主席及行政總裁各自的職責已清楚載於主席及行政總裁職權範圍內。郭博士作為本集團之創辦人，對我們的業務擁有卓越的知識及為零售界之翹楚。因此，董事會認為由同一人身兼公司主席及行政總裁兩職，有利執行本集團的商業策略和發揮其最高營運效益，惟董事會會不時檢討此架構，並於適當時候，考慮將兩職分開。

#### 標準守則


我們已採納不遜於上市規則附錄C3所載列的上市發行人董事進行證券交易的標準守則內有關董事及有關僱員進行證券交易所需標準的標準守則。我們的標準守則已伸延至因職務或工作而可能擁有與本公司或其股份有關的內幕資料的若干有關僱員。我們已收到全體董事及有關僱員確認他們於報告期內已遵守本公司的標準守則。

### 審核委員會

本集團截至2025年9月30日止六個月之未經審核中期業績未經獨立核數師審閱，惟已由本公司審核委員會審閱。

### 中期股息

董事會宣派截至2025年9月30日止六個月之中期股息每股1.15港仙(2024年：每股0.75港仙)，有關股息將派發於2025年12月8日(星期一)名列本公司股東名冊之股東。中期股息預計將於2025年12月19日(星期五)當日或該日前後派發。





## Board of Directors

In accordance with the Company's articles of association, Mrs CHAN KWOK Sze Wai Melody, Ms KWOK Sea Nga Kitty, Ms LEE Yun Chun Marie-Christine and Mr CHUNG Ming Kit retired from office by rotation at the AGM held on 21 August 2025. All of the aforesaid Directors, being eligible, offered themselves for re-election by the Shareholders at the AGM. All voting by the Shareholders were conducted by way of poll and all of the said Directors were duly re-elected at the AGM.

The Directors who held office during the six months ended 30 September 2025 were:

### Executive Directors

Dr KWOK Siu Ming Simon, *SBS, JP* (Chairman and CEO)

- date of appointment: 3 December 1996\*
- date of last re-election in AGM: 22 August 2024

Dr KWOK LAW Kwai Chun Eleanor, *BBS, JP* (Vice-chairman)

- date of appointment: 3 December 1996\*
- date of last re-election in AGM: 22 August 2024

Mrs CHAN KWOK Sze Wai Melody, *MH, JP*

- date of appointment: 2 September 2019\*
- date of last re-election in AGM: 21 August 2025

Ms KWOK Sea Nga Kitty

- date of appointment: 31 August 2022\*
- date of last re-election in AGM: 21 August 2025

Mr CHUNG Ming Kit (CFO and Company Secretary)

- date of appointment: 19 June 2025\*
- date of last re-election in AGM: 21 August 2025

### Independent Non-executive Directors

Ms KI Man Fung Leonie, *GBS, SBS, JP*

- date of appointment: 15 December 2006
- date of last re-election in AGM: 22 August 2024
- term of directorship: three years commencing on 15 December 2024\*

Mr TAN Wee Seng

- date of appointment: 26 June 2012
- date of last re-election in AGM: 24 August 2023
- term of directorship: three years commencing on 26 August 2025\*

\* Subject to the provisions on rotation and retirement in the articles of association of the Company.

## 董事會

根據本公司組織章程細則，陳郭詩慧女士、郭詩雅小姐、利蘊珍女士及鍾明杰先生於2025年8月21日舉行之股東週年大會上輪值退任本公司董事職位。以上所有董事均符合膺選資格並願獲股東於股東週年大會上重選連任。股東之所有投票均以股數投票表決方式進行，而所有上述董事均於該股東週年大會上獲選連任。

於截至2025年9月30日止六個月內，董事會成員為：

### 執行董事

郭少明博士，*銀紫荊星章，太平紳士* (主席及行政總裁)

- 委任日期：1996年12月3日\*
- 上一次獲重選之股東週年大會日期：2024年8月22日

郭羅桂珍博士，*銅紫荊星章，太平紳士* (副主席)

- 委任日期：1996年12月3日\*
- 上一次獲重選之股東週年大會日期：2024年8月22日

陳郭詩慧女士，*榮譽勳章，太平紳士*

- 委任日期：2019年9月2日\*
- 上一次獲重選之股東週年大會日期：2025年8月21日

郭詩雅小姐

- 委任日期：2022年8月31日\*
- 上一次獲重選之股東週年大會日期：2025年8月21日

鍾明杰先生 (首席財務總監及公司秘書)

- 委任日期：2025年6月19日\*
- 上一次獲重選之股東週年大會日期：2025年8月21日

### 獨立非執行董事

紀文鳳小姐，*金紫荊星章，銀紫荊星章，太平紳士*

- 委任日期：2006年12月15日
- 上一次獲重選之股東週年大會日期：2024年8月22日
- 董事任期：由2024年12月15日起計3年\*

陳偉成先生

- 委任日期：2012年6月26日
- 上一次獲重選之股東週年大會日期：2023年8月24日
- 董事任期：由2025年8月26日起計3年\*

\* 須按照本公司章程細則輪值告退。

## SUPPLEMENTARY INFORMATION

### 其他資料

#### Board of Directors (continued)

##### Independent Non-executive Directors (continued)

Mr CHAN Hiu Fung Nicholas, *BBS, MH, JP*

- date of appointment: 2 September 2019
- date of last re-election in AGM: 24 August 2023
- term of directorship: three years commencing on 27 August 2023\*

Ms LEE Yun Chun Marie-Christine

- date of appointment: 2 September 2024
- date of last re-election in AGM: 21 August 2025
- term of directorship: three years commencing on 22 August 2025\*

#### Changes in Director's Particulars

Changes to Mr CHAN Hiu Fung Nicholas's biographical information as follows:

- was elected as Vice Chairman of the China Committee of the Hong Kong General Chamber of Commerce since July 2025; and
- was appointed as an independent non-executive director, member of Related Party Transaction Control and Consumer Rights Protection Committee and Strategy and Investment Committee of Ping An Insurance (Group) Company of China, Ltd., the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong, effective from 15 October 2025.

#### Related Party Transactions

The transactions with related parties disclosed in Note 26 to the condensed consolidated interim financial information do not constitute discloseable connected transactions under the Listing Rules.

#### Issue of Shares

No new shares were issued during the six months ended 30 September 2025.

#### 董事會(續)

##### 獨立非執行董事(續)

陳曉峰先生，銅紫荊星章，榮譽勳章，太平紳士

- 委任日期：2019年9月2日
- 上一次獲重選之股東週年大會日期：2023年8月24日
- 董事任期：由2023年8月27日起計3年\*

利蘊珍女士

- 委任日期：2024年9月2日
- 上一次獲重選之股東週年大會日期：2025年8月21日
- 董事任期：由2025年8月22日起計3年\*

#### 董事詳情變動

陳曉峰先生的資料有以下變更：

- 由2025年7月起獲選為香港總商會中國委員會副主席；及
- 於2025年10月15日獲委任為中國平安保險(集團)股份有限公司(其證券於香港聯交所主板上市)的獨立非執行董事、關聯交易控制與消費者權益保護委員會及戰略與投資決策委員會的成員。

#### 關聯方交易

根據上市規則，於簡明綜合中期財務資料附註26所披露之關聯人士之交易並不構成任何須予披露的關連交易。

#### 發行股份

於截至2025年9月30日止六個月期間，本公司並無發行股份。

\* Subject to the provisions on rotation and retirement in the articles of association of the Company.

\* 須按照本公司章程細則輪值告退。



## Share Options

### (I) 2012 Share Option Scheme

A share option scheme was adopted on 23 August 2012 and became unconditional and effective on 27 August 2012 (the "2012 Share Options Scheme"). The 2012 Share Option Scheme expired on 23 August 2022. Upon expiration of the 2012 Share Option Scheme, no option was available for grant as at 1 April 2025 and 30 September 2025 and no further options were granted under it during the six months period from 1 April 2025 to 30 September 2025 but its provisions continued to govern options granted under this scheme up to and including 23 August 2022. The total number of shares which may be issued upon exercise of all options granted under the scheme was 300,000 Shares, which represented 0.01% of the total issued share capital of the Company as at 30 September 2025. Details of the share options granted under the 2012 Share Option Scheme and their movements during the period are set out below:

				Number of Share Options 購股權數目				
Name 姓名	Date of grant 授予日期	Subscription price per Share 每股股份 認購價 (HK\$) (港元)	Exercise period 行使期	Outstanding as at 1 April 2025 於2025年 4月1日 未獲行使	Granted during the period 於期內授予	Exercised during the period 於期內獲行使	Lapsed during the period 於期內失效	Outstanding as at 30 September 2025 於2025年 9月30日 未獲行使
Directors 董事								
Ms Kl Man Fung Leonie 紀文鳳小姐	13 April 2018 2018年4月13日	4.65	13 April 2020 to 12 April 2028 2020年4月13日至2028年4月12日	100,000	–	–	–	100,000
Mr TAN Wee Seng 陳偉成先生	13 April 2018 2018年4月13日	4.65	13 April 2020 to 12 April 2028 2020年4月13日至2028年4月12日	100,000	–	–	–	100,000
Ms LEE Yun Chun Marie-Christine 利蘊珍女士	13 April 2018 2018年4月13日	4.65	13 April 2020 to 12 April 2028 2020年4月13日至2028年4月12日	100,000	–	–	–	100,000
				300,000	–	–	–	300,000

No share options were cancelled during the period.

The vesting period of all the outstanding share options and share options granted is the period beginning on the date of grant and ending on the date immediately before commencement of the exercise period.

## 購股權

### (I) 2012年購股權計劃

本公司於2012年8月23日採納了一個購股權計劃，該計劃於2012年8月27日無條件生效（「2012年購股權計劃」）。2012年購股權計劃已於2022年8月23日失效。隨著2012年購股權計劃失效，於2025年4月1日及2025年9月30日，並無購股權可予以授出及於2025年4月1日至2025年9月30日的六個月期間並無購股權根據此計劃予以授出，惟該購股權計劃之條文繼續對截至並包括2022年8月23日根據此計劃已授出的購股權具有約束力。於2025年9月30日，根據此計劃所有已授出並予以行使的可予發行的購股權股份總數為300,000股，佔本公司當時已發行股本0.01%。按2012年購股權計劃授出之購股權詳情及於期內之變動載列如下：

期內並無購股權被註銷。

未獲行使的購股權及授予的購股權的歸屬期為由授予日開始直至行使期開始的前一天止。

## **Share Options (continued)**

### **(II) 2022 Share Option Scheme**

Following the expiration of the 2012 Share Option Scheme, the Company adopted a new share option scheme (the "2022 Share Option Scheme") on 31 August 2022. The number of options available for grant under the 2022 Share Option Scheme as at 1 April 2025 and 30 September 2025 was 310,318,945 on both dates. The number of options available for grant under the Service Provider Sublimit as at 1 April 2025 and 30 September 2025 was 31,031,894 shares on both dates. No share options have been granted under the 2022 Share Option Scheme during the six months ended 30 September 2025.

The board of directors of the Company announced that on 8 October 2025, share options carrying the rights to subscribe for a total of 30,490,000 new ordinary shares of HK\$0.10 each of the Company were granted to certain directors and employees of the Group under the 2022 Share Options Scheme. For further details, please refer to the announcement published on 8 October 2025.

## **Share Award Scheme**

The share award scheme was adopted by the Board on 11 April 2014 (the "Share Award Scheme"). Under the Share Award Scheme, the Board may, from time to time, at its absolute discretion, select any eligible employees as selected employees and grant awarded Shares to them at no consideration. The awarded Shares were acquired by the independent trustee, at the costs of the Company, and held under a trust on and subject to, among others, the terms and conditions of the Share Award Scheme. Awarded Shares will be vested in the selected employees according to the terms of grant determined by the Board.

As at 30 September 2025, a total of 8,032,000 awarded Shares had been granted pursuant to the Share Award Scheme, out of which 410,000 awarded Shares remained unvested. During the period, a total of 365,000 awarded Shares lapsed and remained part of the trust fund under the Share Award Scheme.

## **購股權(續)**

### **(II) 2022年購股權計劃**

隨著2012年購股權計劃失效，本公司於2022年8月31日採納了一個新購股權計劃（「2022年購股權計劃」）。於2025年4月1日及2025年9月30日可授出的購股權數目為310,318,945。而於2025年4月1日及2025年9月30日，根據服務提供者分項限額可授出的購股權數目為31,031,894。於截至2025年9月30日止六個月期內並無根據2022年購股權計劃授出任何購股權。

本公司的董事會於2025年10月8日宣佈，根據2022年購股權計劃授出購股權予集團的若干董事及僱員，該等購股權附有權利可認購合共30,490,000股本公司每股面值0.10港元的新普通股。詳情請參閱2025年10月8日刊登的公告。

## **股份獎勵計劃**

董事會於2014年4月11日採納股份獎勵計劃（「股份獎勵計劃」）。根據股份獎勵計劃，董事會可不時全權酌情決定甄選任何合資格僱員為經甄選僱員，並無償向他們授出獎勵股份。獨立受託人將購入股份（費用由本公司承擔）並根據股份獎勵計劃將其作為信託基金的一部分持有。獎勵股份將根據董事會釐定的授出條款歸屬予經甄選僱員。

於2025年9月30日，根據股份獎勵計劃授出合共8,032,000股獎勵股份，其中410,000股獎勵股份尚未歸屬。於期內，根據股份獎勵計劃，共有365,000股獎勵股份失效及其作為信託基金的一部分持有。



## Share Award Scheme (continued)

Details of the awarded Shares granted under the Share Award Scheme and their movements during the six months ended 30 September 2025 are set out below:

## 股份獎勵計劃(續)

股份獎勵計劃授出之獎勵股份詳情及於截至2025年9月30日止六個月內之變動載列如下：


						Number of awarded Shares 獎勵股份數目				
Name 姓名	Date of award 授予日期	Average fair value per Share# 每股平均 公平值# (HK\$) (港元)	Closing price of the Shares immediately before the date on which the awarded shares were granted 緊接獎勵股份 於授予 日期前一天 之收市價 (HK\$) (港元)	Vesting period* 歸屬期*	Weighted average closing price of the Shares immediately before the date on which the awarded Shares were vested 緊接獎勵股份 於歸屬日期 前一天之 加權平均 收市價 (HK\$) (港元)	Outstanding as at 1 April 2025 於2025年 4月1日 未歸屬	Awarded during the period 於期內授予	Vested during the period 於期內歸屬	Lapsed during the period 於期內失效	Outstanding as at 30 September 2025 於2025年 9月30日 未歸屬
Director 董事										
CHUNG Ming Kit 鍾明杰	16 July 2025 2025年7月16日	0.59	0.60	16 July 2025 to 2 December 2027 2025年7月16日至2027年12月2日	-	-	100,000	-	-	100,000
Five highest paid individual during the review period 回顧期內五位最高 薪酬人士	16 July 2025 2025年7月16日	0.59	0.60	16 July 2025 to 11 February 2030 2025年7月16日至2030年2月11日	-	-	300,000	-	(300,000)	-
Employees 僱員										
	8 February 2024 2024年2月8日	0.82	-	8 February 2024 to 19 August 2025 2024年2月8日至2025年8月19日	-	25,000	-	-	(25,000)	-
				8 February 2024 to 19 September 2025 2024年2月8日至2025年9月19日	-	25,000	-	-	(25,000)	-
				8 February 2024 to 20 November 2025 2024年2月8日至2025年11月20日	-	15,000	-	-	(15,000)	-
	12 December 2024 2024年12月12日	0.71	-	12 December 2024 to 1 August 2027 2024年12月12日至2027年8月1日	-	50,000	-	-	-	50,000
				12 December 2024 to 2 July 2027 2024年12月12日至2027年7月2日	-	30,000	-	-	-	30,000
	16 July 2025 2025年7月16日	0.59	0.60	16 July 2025 to 20 January 2030 2025年7月16日至2030年1月20日	-	-	200,000	-	-	200,000
				16 July 2025 to 3 February 2028 2025年7月16日至2028年2月3日	-	-	30,000	-	-	30,000
							145,000	630,000	-	(365,000)

- <sup>#</sup> The fair value of awarded Shares was determined with reference to market price of the Shares at the grant date.
- <sup>\*</sup> The period during which all the specified vesting conditions of the awarded Shares are to be satisfied.

- <sup>#</sup> 獎勵股份的公平值乃參考授予日期股份市價釐定。
- <sup>\*</sup> 為達成所有獎勵股份歸屬條件之期間。

No awarded Shares cancelled during the period.

期內並無獎勵股份被註銷。





## SUPPLEMENTARY INFORMATION 其他資料

### Buy-back, Sale or Redemption of Shares

During the six months ended 30 September 2025, there was no buy-back, sale or redemption of the Company's listed securities by the Company or any of its subsidiaries, except that the trustee of the Share Award Scheme, pursuant to the rules and trust deed of the Share Award Scheme, purchased on the Stock Exchange a total of 600,000 Shares at a total consideration of about HK\$354,000.

### Directors' and Chief Executives' Interests and Short Positions in Shares, Underlying Shares and Debentures

As at 30 September 2025, the interests and short positions of the Directors and chief executives of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code, are set out below:

### 回購、出售或贖回股份

除股份獎勵計劃的受託人根據股份獎勵計劃及信託契約條款，以總額約354,000港元在聯交所購入合共600,000股股份外，本公司及其任何附屬公司於截至2025年9月30日止六個月期內概無回購、出售或贖回本公司任何上市證券。

### 董事及最高行政人員於股份、相關股份及債券之權益及淡倉

於2025年9月30日，本公司董事及最高行政人員於本公司或其任何相聯法團（定義見證券條例第XV部）擁有記載於本公司按證券條例第352條須置存之登記冊內的權益或淡倉，或根據標準守則須知會本公司及聯交所的權益或淡倉如下：

#### (I) Long Position in the Shares, Underlying Shares and Debentures of the Company

#### (II) 擁有本公司股份、相關股份及債券之好倉

Name of Director 董事姓名	Number of Shares in the Company 本公司之股份數目					Approximate percentage of the Shares in issue <sup>(1)</sup> 約佔已發行 股份百分比 <sup>(1)</sup>
	Personal interests 個人權益	Family interests 家族權益	Corporate interests 公司權益	Derivatives interests 衍生工具權益	Total interests 總權益	
Dr KWOK Siu Ming Simon 郭少明博士	40,728,000	–	1,948,734,297 <sup>(2)</sup>	–	1,989,462,297	64.1102%
Dr KWOK LAW Kwai Chun Eleanor 郭羅桂珍博士	–	40,728,000	1,948,734,297 <sup>(2)</sup>	–	1,989,462,297	64.1102%
Mrs CHAN KWOK Sze Wai Melody 陳郭詩慧女士	110,000	6,000	–	–	116,000	0.0037%
Ms KWOK Sea Nga Kitty 郭詩雅小姐	110,000	–	–	–	110,000	0.0035%
Mr CHUNG Ming Kit 鍾明杰先生	1,000,000	–	–	100,000 <sup>(3)</sup>	1,100,000	0.0354%
Ms KI Man Fung Leonie 紀文鳳小姐	–	–	–	100,000 <sup>(3)</sup>	100,000	0.0032%
Mr TAN Wee Seng 陳偉成先生	–	–	–	100,000 <sup>(3)</sup>	100,000	0.0032%
Ms LEE Yun Chun Marie-Christine 利蘊珍女士	–	–	–	100,000 <sup>(3)</sup>	100,000	0.0032%



## Directors' and Chief Executives' Interests and Short Positions in Shares, Underlying Shares and Debentures (continued)

### (I) Long Position in the Shares, Underlying Shares and Debentures of the Company (continued)

Notes:

- (1) Based on 3,103,189,458 Shares in issue as at 30 September 2025.
- (2) These Shares are held as to 1,506,926,594 Shares by Sunrise Height Incorporated, as to 440,407,703 Shares by Green Ravine Limited and as to 1,400,000 Shares by Million Fidelity International Limited. All these companies are owned as to 50% each by Dr KWOK Siu Ming Simon and Dr KWOK LAW Kwai Chun Eleanor.
- (3) Details of the derivatives interests in the shares of the Company of the directors for the six months ended 30 September 2025 are disclosed in the sections of share options scheme on page 55 and share award scheme on page 57 of this report.

### (II) Long Position in the Shares, Underlying Shares and Debentures of Associated Corporations

Dr KWOK Siu Ming Simon and Dr KWOK LAW Kwai Chun Eleanor are each taken to be interested in all the issued non-voting deferred shares (the "Deferred Shares") of Base Sun Investment Limited ("Base Sun"), Matford Trading Limited ("Matford"), Sa Sa Cosmetic Company Limited and Sa Sa Investment (HK) Limited, all of which are wholly-owned subsidiaries of the Company.

Details of interests in the Deferred Shares as at 30 September 2025 are set out below:

Name of associated corporation 相聯法團名稱	Dr KWOK Siu Ming Simon: Number of Deferred Shares in associated corporation 郭少明博士：相聯法團之遞延股份數目					Percentage of shareholding to all the Deferred Shares of associated corporation 佔相聯法團之所有遞延股份百分比
	Personal interests 個人權益	Family interests 家族權益	Corporate interests 公司權益	Other interests 其他權益	Total interests 總權益	
Base Sun Investment Limited 鵬日投資有限公司	–	–	2 <sup>(1)</sup>	–	2	100%
Matford Trading Limited 美福貿易有限公司	3 <sup>(2)</sup>	–	–	–	3	50%
Sa Sa Cosmetic Company Limited 莎莎化粧品有限公司	1	–	–	–	1	50%
Sa Sa Investment (HK) Limited 莎莎投資(香港)有限公司	1	–	–	–	1	50%

## 董事及最高行政人員於股份、相關股份及債券之權益及淡倉(續)

### (I) 擁有本公司股份、相關股份及債券之好倉(續)

附註：

- (1) 根據於2025年9月30日的已發行股份3,103,189,458股計算。
- (2) 該等股份其中1,506,926,594股由Sunrise Height Incorporated持有，440,407,703股由Green Ravine Limited持有，而1,400,000股由萬揚國際有限公司持有。郭少明博士及郭羅桂珍博士各持有50%權益。
- (3) 有關董事於截至2025年9月30日止六個月期間擁有股份之衍生工具權益的詳情及變動已於本報告第55頁之購股權計劃及第57頁之股份獎勵計劃部份披露。

### (II) 擁有相聯法團股份、相關股份及債券之好倉

郭少明博士及郭羅桂珍博士分別被視為擁有鵬日投資有限公司(「鵬日」)、美福貿易有限公司(「美福」)、莎莎化粧品有限公司及莎莎投資(香港)有限公司之全部已發行無投票權遞延股份(「遞延股份」)之權益，前述公司均為本公司全資附屬公司。

於2025年9月30日，遞延股份之權益詳情載列如下：



## SUPPLEMENTARY INFORMATION

### 其他資料

#### Directors' and Chief Executives' Interests and Short Positions in Shares, Underlying Shares and Debentures (continued)

#### 董事及最高行政人員於股份、相關股份及債券之權益及淡倉(續)

#### (II) Long Position in the Shares, Underlying Shares and Debentures of Associated Corporations (continued)

#### (III) 擁有相聯法團股份、相關股份及債券之好倉(續)

Name of associated corporation 相聯法團名稱	Dr KWOK LAW Kwai Chun Eleanor: Number of Deferred Shares in associated corporation 郭羅桂珍博士：相聯法團之遞延股份數目					Percentage of shareholding to all the Deferred Shares of associated corporation 佔相聯法團之所有遞延股份百分比
	Personal interests 個人權益	Family interests 家族權益	Corporate interests 公司權益	Other interests 其他權益	Total interests 總權益	
Base Sun Investment Limited 鵬日投資有限公司	–	–	2 <sup>(1)</sup>	–	2	100%
Matford Trading Limited 美福貿易有限公司	3 <sup>(2)</sup>	–	–	–	3	50%
Sa Sa Cosmetic Company Limited 莎莎化粧品有限公司	1	–	–	–	1	50%
Sa Sa Investment (HK) Limited 莎莎投資(香港)有限公司	1	–	–	–	1	50%

Notes:

- Dr KWOK Siu Ming Simon and Dr KWOK LAW Kwai Chun Eleanor together hold two Deferred Shares in Base Sun through Win Win Group International Limited ("Win Win") and Modern Capital Investment Limited ("Modern Capital"). Win Win and Modern Capital are companies beneficially owned as to 50% each by Dr KWOK Siu Ming Simon and Dr KWOK LAW Kwai Chun Eleanor and each of Win Win and Modern Capital holds one Deferred Share in Base Sun.
- Dr KWOK Siu Ming Simon holds three Deferred Shares in Matford through Mr YUNG Leung Wai Tony who acts as a nominee shareholder.
- Dr KWOK LAW Kwai Chun Eleanor holds three Deferred Shares in Matford through Ms KWOK Lai Yee Mabel who acts as a nominee shareholder.

附註：

- 郭少明博士及郭羅桂珍博士透過威威集團國際有限公司(「威威」)及茂傑投資有限公司(「茂傑」)持有鵬日兩股遞延股份。郭少明博士及郭羅桂珍博士各持有威威及茂傑50%權益，而威威和茂傑各持有一股鵬日遞延股份。
- 郭少明博士透過容良偉先生(作為其代理人股東)持有美福三股遞延股份。
- 郭羅桂珍博士透過郭麗儀小姐(作為其代理人股東)持有美福三股遞延股份。

Save as disclosed above, no director or chief executive of the Company has any interests or short position in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

除上文所披露者外，本公司各董事及最高行政人員概無在本公司或其相聯法團(定義見證券條例第XV部)的股份、相關股份及債券中擁有記載於本公司按證券條例第352條須置存之登記冊內的權益或淡倉，或根據標準守則須知會本公司及聯交所的權益或淡倉。

#### Directors' Benefits from Rights to Acquire Shares or Debentures

#### 董事購買股份或債券權利之利益

Save as disclosed under the sections of share option scheme on page 55 and share award scheme on page 57, at no time during the period was the Company or its subsidiaries, a party to any arrangements which enabled any of the Directors (including their spouses or children under 18 years of age), to acquire benefits by means of acquisition of shares in or debenture of the Company or any other body corporate.

除於第55頁之購股權計劃及第57頁之股份獎勵計劃部分所披露者外，本公司或其附屬公司於期內任何時間概無成為任何安排之其中一方，令董事(包括彼等之配偶或18歲以下之子女)可藉收購本公司或任何其他法人團體之股份或債券而獲得利益。





## Interests and Short Positions in Shares and Underlying Shares of Substantial Shareholders

As at 30 September 2025, substantial shareholders, other than a director or chief executive of the Company, who had interests and short positions in the shares and underlying shares of the Company which were recorded in the register of interests required to be kept by the Company under Section 336 of the SFO are as follows:

### Long Position of Substantial Shareholders in the Shares

Name of Substantial Shareholder 主要股東名稱	Capacity 身份	No. of Shares held 持股量	Approximate percentage shareholding <sup>(1)</sup> 約佔已發行股份之百分比 <sup>(1)</sup>
Sunrise Height Incorporated <sup>(2)</sup>	Beneficial owner 實益擁有人	1,506,926,594	48.56%
Green Ravine Limited <sup>(2)</sup>	Beneficial owner 實益擁有人	440,407,703	14.19%

Notes:

- (1) Based on 3,103,189,458 Shares in issue as at 30 September 2025.
- (2) Both Sunrise Height Incorporated and Green Ravine Limited are owned as to 50% each by Dr KWOK Siu Ming Simon and Dr KWOK LAW Kwai Chun Eleanor.

## 主要股東於股份及相關股份之權益及淡倉

於2025年9月30日，根據證券條例第336條須置存之登記冊內所載，下列人士（本公司任何董事或最高行政人員除外）為主要股東，並於本公司的股份及相關股份中擁有權益或淡倉：

### 主要股東擁有本公司股份之好倉

附註：

- (1) 根據於2025年9月30日的已發行股份3,103,189,458股計算。
- (2) 郭少明博士及郭羅桂珍博士各擁有 Sunrise Height Incorporated及Green Ravine Limited 50%股權。

## Interests and Short Positions in Shares and Underlying Shares of Other Persons

As at 30 September 2025, the Company has not been notified of any persons (other than the directors or chief executives or substantial shareholders of the Company) who had interests or short positions in the shares or underlying shares of the Company as recorded in the register to be kept under Section 336 of the SFO.

## 其他人士於股份及相關股份之權益及淡倉

於2025年9月30日，本公司並無知悉任何人士（本公司任何董事或最高行政人員或主要股東除外）擁有根據證券條例第336條須置存之登記冊內所載之本公司的股份及相關股份中擁有權益或淡倉。

## Specific Performance Obligation on Controlling Shareholder

As disclosed in the Company's announcement dated 7 August 2020, Sa Sa Cosmetic Company Limited (an indirect wholly-owned subsidiary of the Company) as borrower obtained general banking facilities from a bank to finance the working capital requirements of the Group. Such banking facilities are provided by way of two revolving loan facilities up to an aggregate amount of HK\$80,000,000 with no specific tenor, which may be modified, cancelled or suspended at any time without prior notice at the bank's sole discretion.

It is a condition of the banking facilities, among others, that Dr KWOK Siu Ming Simon and/or his family members shall maintain (whether directly or indirectly) not less than 51% shareholding of the Company, and Dr KWOK Siu Ming Simon shall remain as chairman of the Board.

## 控股股東之特定履行責任

誠如本公司於2020年8月7日刊發的公告所披露，本公司之間接全資附屬公司莎莎化粧品有限公司作為借方獲得由銀行提供的銀行融資以資助本集團之營運資金。此銀行融資將以兩項循環貸款提供，總額為八千萬港元，沒有特定期限，但銀行可隨時在未經事先通知之情況下全權酌情修改、取消或中止該融資。

該銀行融資有一項條款，除其他外，郭少明博士及／或其家庭成員需要（直接或間接）持有本公司不少於51%的股份及郭少明博士需繼續擔任本公司董事會主席。

